AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
Amarin Corporation plc (NASDAQ:AMRN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Operator Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin.
-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA –
18 Apr 2025 Date | | - Cons. EPS | - EPS |
12 Mar 2025 Date | | - Cons. EPS | - EPS |
31 Jul 2024 Date | | - Cons. EPS | - EPS |
1 May 2024 Date | | - Cons. EPS | - EPS |
29 Feb 2024 Date | | - Cons. EPS | - EPS |
18 Apr 2025 Date | | - Cons. EPS | - EPS |
12 Mar 2025 Date | | - Cons. EPS | - EPS |
31 Jul 2024 Date | | - Cons. EPS | - EPS |
1 May 2024 Date | | - Cons. EPS | - EPS |
29 Feb 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Mr. Aaron D. Berg CEO | XSTU Exchange | US0231112063 ISIN |
IE Country | 275 Employees | - Last Dividend | 11 Apr 2025 Last Split | - IPO Date |
Amarin Corporation plc stands as a noteworthy entity within the pharmaceutical landscape, dedicating its efforts to developing and commercializing therapeutic treatments aimed at combating cardiovascular diseases. With a geographical footprint spanning the United States, various European countries, Canada, Lebanon, and the United Arab Emirates, Amarin has established a significant presence in the global healthcare sector. The company's journey began under the name Ethical Holdings plc but underwent a rebranding to Amarin Corporation plc in 1999, marking a new chapter in its history. Since its inception in 1989, Amarin has been headquartered in Dublin, Ireland, serving as a testament to its enduring commitment to advancing cardiovascular health through innovative pharmaceutical solutions. At the heart of its collaborative endeavors is a strategic partnership with Mochida Pharmaceutical Co., Ltd., focusing on the development and commercialization of drug products and new therapeutic indications derived from the active pharmaceutical ingredient in its flagship product, Vascepa.
VASCEPA stands out as Amarin Corporation plc's premier product offering, distinguished by its formulation as a prescription-only omega-3 fatty acid. This distinctive pharmacological product is specifically designed as an adjunct to diet for the purpose of reducing triglyceride levels in adult patients diagnosed with severe hypertriglyceridemia. The commercialization of VASCEPA primarily targets wholesalers and specialty pharmacy providers, thereby ensuring its accessibility to the patient population in need of this critical intervention for managing cardiovascular health. Through this endeavor, Amarin accentuates its commitment to addressing the intricate challenges associated with cardiovascular diseases, leveraging the therapeutic potential of omega-3 fatty acids to enhance patient outcomes.